Drug
Ixazomib clinical trials
Also written MLN9708, Ninlaro and MLN-2238.
- studies test it
- 126
- open now
- 4
- in phase 3
- 10
- first study started
- 2009
Keep track of what changes. Save the ixazomib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Ninlaro
- 45
Combined with it in one product
Studies by the year they started
126 studies that test it; most in 2015 (21)
| Year | Studies |
|---|---|
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 17 |
| 2015 | 21 |
| 2016 | 14 |
| 2017 | 12 |
| 2018 | 17 |
| 2019 | 12 |
| 2020 | 7 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 54
- Phase 2
- 82
- Phase 3
- 10
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 97
Millennium Pharmaceuticals, Inc. (18) · Mayo Clinic (10) · Takeda (10) · M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (4) · Nantes University Hospital (2) · Alliance for Clinical Trials in Oncology (2)
Often tested with
Tested in the same studies.
Dexamethasone (52) · Lenalidomide (22) · Daratumumab (10) · Pomalidomide (9) · Rituximab (6) · Cyclophosphamide (5) · Venetoclax (3) · Doxorubicin (3)
Studies
Open first, then newest update. How each study uses ixazomib is read from its arms, and is right about nine times in ten.
Testing it · 126
- A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir SizeNot yet recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07881809Written as Ixazomib 4 mg
- Trial of Ixazomib for Kaposi SarcomaRecruitingPhase 2AIDS Malignancy ConsortiumNCT04305691Written as Ixazomib Citrate
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05722405Written as Ixazomib plus low-dose lenalidomide
- Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)RecruitingPhase 2Ho Sup LeeNCT03616782Written as Ixazomib
- Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03763162Written as Ixazomib
- Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedPhase 2Fred Hutchinson Cancer CenterNCT02619682Written as Ixazomib Citrate
- Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedPhase 2Nantes University HospitalNCT01936532Written as MLN9708
- Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT03587662Written as Ixazomib
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04847453Written as Ixazomib Citrate
- Daratumumab, Ixazomib, and Dexamethasone in AL AmyloidosisCompletedPhase 1M.D. Anderson Cancer CenterNCT03283917Written as Ixazomib
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 2University of WashingtonNCT02339922Written as Ixazomib Citrate
- Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedPhase 3Alliance for Clinical Trials in OncologyNCT02516423Written as ixazomib
- A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaCompletedPhase 1/2PrECOG, LLC.NCT03323151Written as Ixazomib
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 3CelgeneNCT03651128Written as Ixazomib
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingPhase 2Nantes University HospitalNCT04998786Written as Ixazomib
- Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaTerminatedPhase 2University Hospital, CaenNCT03757221Written as Ixazomib and Daratumumab
- Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)TerminatedPhase 1/2University of Michigan Rogel Cancer CenterNCT03547700Written as Ixazomib
- Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedPhase 2Mayo ClinicNCT03506373Written as Ixazomib Citrate
- A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)TerminatedPhase 4TakedaNCT03173092Written as Ixazomib
- Ixazomib + Pomalidomide + Dexamethasone In MMActive, not recruitingPhase 1/2Omar Nadeem, MDNCT04094961Written as Ixazomib
See all 126 studies that test ixazomib →
Given in every arm · 15 — ixazomib is usual care beside what is tested
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Ixazomib
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Ixazomib
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedPhase 2Larysa SanchezNCT04052880Written as Ixazomib
- Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibCompletedPhase 2Mayo ClinicNCT01415882Written as Ixazomib Citrate
- Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple MyelomaCompletedPhase 2GWT-TUD GmbHNCT03731832Written as MLN9708
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedPhase 2Emory UniversityNCT02765854Written as Ixazomib
- PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaActive, not recruitingPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT03817320Written as Ixazomib
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2Emory UniversityNCT03942224Written as Ixazomib
- STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedPhase 2Mario BoccadoroNCT02586038Written as MLN9708
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedPhase 2OncotherapeuticsNCT03733691Written as Ixazomib
- A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnPhase 4TakedaNCT05183139Written as Ixazomib
- Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2Parameswaran HariNCT02477215Written as MLN9708
- Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain AmyloidosisCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01318902Written as Ixazomib
- A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)TerminatedPhase 1TakedaNCT04272775Written as Ixazomib
- Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnPhase 1/2National Cancer Institute (NCI)NCT03856112Written as Ixazomib
As the comparator · 2 — what is tested is compared with ixazomib
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingPhase 1/2Columbia UniversityNCT05451771Written as Ixazomib
- IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedPhase 3Millennium Pharmaceuticals, Inc.NCT01850524Written as Ixazomib
Codes
What other systems call ixazomib · ClinicalTrials.gg INT005598
- MeSH (NLM) C548400ixazomibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 71050168A2IXAZOMIBConfirmed FDA, NLM, Wikidata
- RxNorm 1723735Confirmed FDA, Wikidata
- Wikidata Q20948663ixazomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97940IxazomibOne source FDA
- DrugBank DB09570One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C548400 | ixazomib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 71050168A2 | IXAZOMIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1723735 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20948663 | ixazomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97940 | Ixazomib | One source FDA |
| DrugBank | DB09570 | — | One source Wikidata |
Also registered as ixazomib citrate (UNII 46CWK97Z3K · RxNorm 1723734).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.